Our focus lies in developing a peptide with scientifically validated potential to transform the treatment of fibrosis and related conditions. This scientific foundation underscores our dedication to translating cutting-edge discoveries into impactful solutions for patients worldwide.
This peptide, was identified through groundbreaking research, showcases exceptional activity in inhibiting key pathways associated with fibrotic diseases, highlighting its promise as a cornerstone for future therapies.
Ezquerro et al (PMID: 12946101) identified in 2003 a synthetic peptide derived from the type III receptor of Transforming Growth Factor Beta (TGF-β), a cytokine central to the development of fibrosis. This peptide has demonstrated remarkable antifibrotic properties in preclinical studies, both in vitro and in vivo. By inhibiting the binding and activity of TGF-β, the peptide effectively reduces the activation of hepatic stellate cells—key drivers of fibrosis—and minimizes collagen deposition in the liver.
In animal models of liver injury, treatment with the peptide significantly decreased fibrotic markers and improved liver tissue architecture. These results validate its potential as a therapeutic tool to combat liver fibrosis and other TGF-β-mediated conditions, offering hope for improved treatment options in diseases that currently lack effective solutions.
